SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally
US drugmaker SIGA Technologies said it has received new orders worth $28 million for its oral antiviral drug TPOXX, as monkeypox cases continue to rise in countries where the disease is not usually seen.
TPOXX (tecovirimat) is approved in the European Union and United Kingdom to treat diseases caused by the family of orthopoxvirus that includes smallpox, monkeypox and cowpox. It is only approved to treat smallpox in the United States and Canada.
SIGA said the new orders include $2 million worth of initial procurement from two countries in Europe and Asia Pacific as well as another $26 million from Canada under existing contracts. The company expects at least $26 million of international deliveries by September 30, including deliveries made in the second quarter.
The uptick in orders comes at a time when more than 7,600 confirmed cases of monkeypox have been reported from 50 countries where the disease is not endemic.
Monkeypox is a viral disease that causes flu-like symptoms and skin lesions. It spreads through close contact and many recent cases have been reported in men who have sex with men, though it is not defined as a sexually transmitted infection.
The strain currently circulating in the Northern Hemisphere has an estimated fatality rate of between 3% and 6% and is considered especially dangerous for children and those with weak immune systems.
In addition to stocking up on oral medication, many countries have placed orders for Bavarian Nordic’s Imvanex vaccine, which is sold under the brand name Jynneos in the United States.
The World Health Organisation has so far held off on declaring the monkeypox outbreak a global health emergency, but it will meet next week to re-evaluate whether it warrants this designation. The ‘global emergency’ label currently only applies to the coronavirus pandemic and efforts to eradicate polio.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance